Elsevier

Disease-a-Month

Volume 37, Issue 12, December 1991, Pages 749-810
Disease-a-Month

Non-endocrine applications of somatostatin and octreotide acetate: facts and flights of fancy

https://doi.org/10.1016/S0011-5029(05)80015-XGet rights and content

Abstract

Somatostatin, originally detected by Krulich and ultimately isolated by Brazeau, was initially described as a growth hormone rlease-inhibiting factor. Subsequent investigation into the use of native somatostatin and the development of long-acting somatostatin analogues, especially octreotide acetate, have fostered increasing uses of these compounds. Though the clinical and investigational uses of somatostatin and its analogues are varied, one central theme remains constant: the ability of these agents to suppress circulating peptide levels. This article, a review of the current non-endocrine applications of somatostatin and its analogues, covers a wide range of potential applications for somatostatin-like compounds. These include use in cirrhosis and variceal bleeding, peptic ulcer disease, pancreatic fistulas, acute and chronic pancreatitis, dumping syndrome, cancer therapy, small bowel fistulas, psoriasis, pain control, and autonomic hypotension. Somatostatin may also play a role in the development and potential treatment of neurologic disease and may have profound influence on behavior.

Section snippets

Everett J. Mozell received his M.D. from Upstate Medical Center in Syracuse, New York in 1983. He completed his general surgical training at the Oregon Health Sciences University in Portland, Oregon before undertaking a thoracic surgery fellowship in England. He currently is a clinical research assistant at Oregon Health Sciences University and is in private surgical practice at the Salem Clinic in Salem, Oregon. His research interests include endocrine and non-endocrine tumors of the pancreas.

References (263)

  • Gomez-PanA et al.

    Direct inhibition of gastric acid and pepsin secretion by growth hormone release-inhibiting hormone in cats

    Lancet

    (1975)
  • SandvikA et al.

    The effect of somatostatin on baseline and stimulated acid secretion and vascular histamine release from the totally isolated vascularly perfused rat stomach

    Regul Pept

    (1988)
  • ChibaT et al.

    Effects of glucagon, secretin and vasoactive intestinal polypeptide on gastric somatostatin and gastrin release from isolated perfused rat stomach

    Gastroenterology

    (1980)
  • MartindaleR et al.

    Differential regulation of gastrin and somatostatin secretion from isolated perfused rat stomachs

    Gastroenterology

    (1982)
  • WolfeM et al.

    Effects of carbachol on gastrin and somatostatin release in rat antral tissue culture

    Gastroenterology

    (1984)
  • HartyR et al.

    Somatostatin inhibition of basal and carbachol-stimulated gastrin release in rat antral organ culture

    Gastroenterology

    (1981)
  • HongS et al.

    Somatostatin modulation of neurally mediated pepsinogen secretion from frog esophageal mucosa

    Biochim Biophys Acta

    (1988)
  • SomervilleKW et al.

    Somatostatin in the treatment of haematemesis and melaena

    Lancet

    (1985)
  • KayassehL et al.

    Somatostatin and cimetidine in peptic ulcer haemorrhage: a randomised controlled trial

    Lancet

    (1980)
  • LimbergB et al.

    Somatostatin for cimetidine-resistant gastroduodenal hemorrhage

    Lancet

    (1980)
  • GreenF et al.

    Effect of acid and pepsin on blood coagulation and platelet aggregation: a possible contributor to prolonged gastroduodenal mucosal hemorrhage

    Gastroenterology

    (1978)
  • KonturekSJ et al.

    Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats

    Gastroenterology

    (1988)
  • RaptisS et al.

    Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones

    Metabolism

    (1978)
  • PrinzR et al.

    Treatment of pancreatic cutaneous fistula with a somatostatin analogue

    Am J Surg

    (1988)
  • WolteringEA et al.

    Treatment of nonendocrine gastrointestinal disorders with octreotide acetate

    Metabolism

    (1990)
  • WilliamsS et al.

    Effect of octreotide acetate on pancreatic exocrine function

    Am J Surg

    (1989)
  • KrulichL et al.

    Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro

    Endocrinology

    (1968)
  • BrazeauP et al.

    Hypothalamic peptide that inhibits immunoreactive pituitary growth hormone

    Science

    (1973)
  • ValeW et al.

    Effects of somatostatin on the secretion of thyrotropin and prolactin

    Endocrinology

    (1974)
  • HellmanB et al.

    Inhibition of the in vitro secretion of insulin by an extract of pancreatic α1 cells

    Endocrinology

    (1969)
  • PedersonR et al.

    The effect of somatostatin on release and insulinotropic action of gastric inhibitory polypeptide

    Can J Physiol Pharmacol

    (1975)
  • PetelY et al.

    Somatostatin: some aspects of its physiology

  • MarcoJ et al.

    Inhibitory effect of somatostatin on human pancreatic polypeptide secretion

    Life Sci

    (1977)
  • BloomSR et al.

    Proceedings: Effect of somatostatin on motilin and gastric emptying

    Gut

    (1975)
  • BodenG et al.

    Somatostatin suppresses secretin and pancreatic exocrine secretion

    Science

    (1975)
  • OseiK et al.

    Effects of somatostatin and gastroenteropancreatic hormones in a malignant insulinoma patient

    Clin Res

    (1985)
  • MozellE et al.

    Adult onset nesidioblastosis: response of glucose, insulin and secondary peptides to therapy with sandostatin

    Am J Gastroenterol

    (1990)
  • MozellE et al.

    Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome

    Surg Gynecol Obstet

    (1990)
  • BodenG et al.

    Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995

    N Engl J Med

    (1986)
  • BrabantG et al.

    Treatment of carcinoid syndrome and VIPoma with a long-acting somatostatin analogue (SMS 201-995)

    Scand J Gastroenterol

    (1986)
  • TolisG

    Long-term management of acromegaly with sandostatin

    Horm Res

    (1988)
  • LambertsSW et al.

    The sensitivity of growth hormone and prolactin secretion to the somatostatin analog SMS 201-995 in patients with prolactinomas and acromegaly

    Clin Endocrinol

    (1986)
  • Beck-PeccozP et al.

    Treatment of inappropriate secretion of thyrotropin with somatostatin analog SMS 201-995

    Horm Res

    (1988)
  • NavascuesI et al.

    Effect of a long-acting somatostatin derivative SMS 201-995 (Sandostatin) on glucose homeostasis in type I diabetes mellitus

    Horm Res

    (1988)
  • GerichJE et al.

    Prevention of human diabetic ketoacidosis by somatostatin: evidence for an essential role of glucagon

    N Engl J Med

    (1975)
  • LevinG et al.

    Effects of somatostatin on gallbladder emptying in man

    Clin Res

    (1983)
  • BolaffiJ et al.

    Somatostatin: occurrence in urinary bladder epithelium and renal tubules of the toad, buto marinus

    Science

    (1980)
  • YamadaY et al.

    Immunohistochemical demonstration of somatostatin-containing cells in the human, dog and rat thyroids

    Tohoku J Exp Med

    (1977)
  • Bennett-ClarkC et al.

    Distribution of somatostatin in the rat brain: telencephalon and diencephalon

    Brain Res

    (1988)
  • JenkinsS et al.

    Effects of a somatostatin analogue SMS 201-995 in hepatic hemodynamics in the pig and on intravariceal pressure in man

    Br J Surg

    (1985)
  • Cited by (0)

    Everett J. Mozell received his M.D. from Upstate Medical Center in Syracuse, New York in 1983. He completed his general surgical training at the Oregon Health Sciences University in Portland, Oregon before undertaking a thoracic surgery fellowship in England. He currently is a clinical research assistant at Oregon Health Sciences University and is in private surgical practice at the Salem Clinic in Salem, Oregon. His research interests include endocrine and non-endocrine tumors of the pancreas.

    Eugene A. Woltering is Associate Professor of Surgery in the Division of Surgical Oncology of Oregon Health Sciences University in Portland, Oregon. After completing a general surgical residency at Vanderbilt University he trained in surgical oncology at the National Cancer Institute and Ohio State University. His major clinical interests are endocrine surgery and breast disease. His research interests include the study of mechanisms of peptide hormone action and tumor angiogenesis.

    Thomas M. O'Dorisio is professor of Physiology and Endocrinology at Ohio State University, Director of the Division of Endocrinology at Ohio State University, Director of the Division of Endocrinology and Metabolism, and Associate Program Director at Ohio State University Clinical Research Center. He has been affiliated with Ohio State University for the past 17 years. His major research interests are gastrointestinal hormones, endocrine tumors of the gastrointestinal tract, and diabetes mellitus.

    View full text